Prosight Management’s Maravai LifeSciences MRVI Stock Holding History

Prosight Management’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-208,200	Closed	-$1.73M	–	43
2024 Q3	$1.73M	Buy	+208,200	New	+$1.8M	0.43%	36
2024 Q2	–	Sell	-599,460	Closed	-$5.2M	–	52
2024 Q1	$5.2M	Buy	+599,460	New	+$4.06M	1.45%	21
2023 Q3	–	Sell	-314,300	Closed	-$3.91M	–	45
2023 Q2	$3.91M	Buy	+314,300	New	+$4.24M	1.14%	26
2022 Q4	–	Sell	-8,540	Closed	-$218K	–	47
2022 Q3	$218K	Buy	+8,540	New	+$214K	0.12%	38

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

1WCM

12 West Capital Management New York $535M AUM 25.99% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Prosight Management's MRVI Position: Q4 2024 in Review

Prosight Management sold out of Maravai LifeSciences (MRVI) in Q4 2024, closing a stake of 208,200 shares — an estimated $1.73M sold.

Prosight Management first reported a position in MRVI in Q3 2022 and held it in 4 quarters. The position peaked at $5.2M in Q1 2024. 185 funds tracked by Wall St. Rank hold MRVI as of Q4 2024.

Prosight Management reported no remaining Maravai LifeSciences position as of Q4 2024 after selling out during the quarter.
Prosight Management sold 208,200 Maravai LifeSciences shares in Q4 2024, an estimated $1.73M.
Prosight Management first reported a position in Maravai LifeSciences in Q3 2022 and held it in 4 quarters.
Prosight Management's Maravai LifeSciences position peaked at $5.2M in Q1 2024.
185 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q4 2024.

Based on Prosight Management's 13F filing for Q4 2024, filed 14 Feb 2025.